Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
NCT ID: NCT03164291
Last Updated: 2017-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
170 participants
INTERVENTIONAL
1984-06-30
2017-05-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or intolerant of rifampin.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens
NCT02410772
Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients
NCT00810407
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
NCT00694629
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
NCT03474029
TMC207 +/- Rifabutin/Rifampin
NCT01341184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rifabutin
Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)
Rifabutin
Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rifabutin
Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnancy
* Low platelet count, except with very serious disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
The University of Texas Health Science Center at Tyler
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Richard J. Wallace, Jr., M.D.
Chairman Department of Microbiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard J Wallace, Jr, M.D.
Role: PRINCIPAL_INVESTIGATOR
The University of Texas Health Center at Tyler
William B Girard, MD
Role: STUDY_CHAIR
University of Texas Health Science Center IRB Chair
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Texas Health Science Center at Tyler
Tyler, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
072
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.